» Articles » PMID: 37323925

Decomposing Interaction and Mediating Effects of Race/ethnicity and Circulating Blood Levels of Cystatin C on Cognitive Status in the United States Health and Retirement Study

Overview
Specialty Neurology
Date 2023 Jun 16
PMID 37323925
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Elevated circulating cystatin C is associated with cognitive impairment in non-Hispanic Whites, but its role in racial disparities in dementia is understudied. In a nationally representative sample of older non-Hispanic White, non-Hispanic Black, and Hispanic adults in the United States, we use mediation-interaction analysis to understand how racial disparities in the cystatin C physiological pathway may contribute to racial disparities in prevalent dementia.

Methods: In a pooled cross-sectional sample of the Health and Retirement Study ( = 9,923), we employed Poisson regression to estimate prevalence ratios and to test the relationship between elevated cystatin C (>1.24 vs. ≤1.24 mg/L) and impaired cognition, adjusted for demographics, behavioral risk factors, other biomarkers, and chronic conditions. Self-reported racialized social categories were a proxy measure for exposure to racism. We calculated additive interaction measures and conducted four-way mediation-interaction decomposition analysis to test the moderating effect of race/ethnicity and mediating effect of cystatin C on the racial disparity.

Results: Overall, elevated cystatin C was associated with dementia (prevalence ratio [PR] = 1.2; 95% CI: 1.0, 1.5). Among non-Hispanic Black relative to non-Hispanic White participants, the relative excess risk due to interaction was 0.7 (95% CI: -0.1, 2.4), the attributable proportion was 0.1 (95% CI: -0.2, 0.4), and the synergy index was 1.1 (95% CI: 0.8, 1.8) in a fully adjusted model. Elevated cystatin C was estimated to account for 2% (95% CI: -0, 4%) for the racial disparity in prevalent dementia, and the interaction accounted for 8% (95% CI: -5, 22%). Analyses for Hispanic relative to non-white participants suggested moderation by race/ethnicity, but not mediation.

Discussion: Elevated cystatin C was associated with dementia prevalence. Our mediation-interaction decomposition analysis suggested that the effect of elevated cystatin C on the racial disparity might be moderated by race/ethnicity, which indicates that the racialization process affects not only the distribution of circulating cystatin C across minoritized racial groups, but also the strength of association between the biomarker and dementia prevalence. These results provide evidence that cystatin C is associated with adverse brain health and this effect is larger than expected for individuals racialized as minorities had they been racialized and treated as non-Hispanic White.

Citing Articles

Cystatins: unravelling the biological implications for neuroprotection.

Stanczykiewicz B, Luc M, Banach M, Zablocka A Arch Med Sci. 2024; 20(1):157-166.

PMID: 38414464 PMC: 10895963. DOI: 10.5114/aoms/171706.


The Worst of Times: Depressive Symptoms Among Racialized Groups Living With Dementia and Cognitive Impairment During the COVID-19 Pandemic.

Brown M, Adkins-Jackson P, Sayed L, Wang F, Leggett A, Ryan L J Aging Health. 2023; 36(9):535-545.

PMID: 38128585 PMC: 11542616. DOI: 10.1177/08982643231223555.

References
1.
Assmann S, Hosmer D, Lemeshow S, Mundt K . Confidence intervals for measures of interaction. Epidemiology. 1996; 7(3):286-90. DOI: 10.1097/00001648-199605000-00012. View

2.
Asad A, Clair M . Racialized legal status as a social determinant of health. Soc Sci Med. 2017; 199:19-28. DOI: 10.1016/j.socscimed.2017.03.010. View

3.
Madero M, Wassel C, Peralta C, Najjar S, Sutton-Tyrrell K, Fried L . Cystatin C associates with arterial stiffness in older adults. J Am Soc Nephrol. 2009; 20(5):1086-93. PMC: 2678034. DOI: 10.1681/ASN.2008030318. View

4.
Geronimus A, Hicken M, Keene D, Bound J . "Weathering" and age patterns of allostatic load scores among blacks and whites in the United States. Am J Public Health. 2005; 96(5):826-33. PMC: 1470581. DOI: 10.2105/AJPH.2004.060749. View

5.
Nicholas S, Kalantar-Zadeh K, Norris K . Racial disparities in kidney disease outcomes. Semin Nephrol. 2013; 33(5):409-15. PMC: 3983362. DOI: 10.1016/j.semnephrol.2013.07.002. View